Inforlife Sa Patent-Cliff Exposure & CMS Drug Spending Portfolio

Inforlife Sa (US): 3 reconciled FDA prescription therapies, $2.6M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2038-01-01
2024 CMS Total Public Spend$2.6M
2024 Medicare Part D Spend$438K
2024 Medicaid Spend$2.2M
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel